Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI351 (fluzerese) + rasatet for first-line KRAS G12C-mutant advanced NSCLC (single-arm phase II)
ChiCTR2600128046Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jul 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fulzerasib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Objective response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
fulzerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600128046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128046.